Company Overview of Envisia Therapeutics Inc.
Envisia Therapeutics Inc. is engaged in the discovery and development of ocular therapeutics for the critical needs in ophthalmology. The company offers ENV515, a prostaglandin analogue that uses a biodegradable PRINT particle formulation to provide sustained intraocular pressure reduction over months. It also provides glaucoma drug therapies that include PRINT particle therapeutics to overcome biologic, chemical, or other barriers that limit existing ocular therapies; therapeutics based on biocompatible polymers for the delivery of medicines with extended-release kinetics; and topical therapies for treating ocular diseases. The company was founded in 2013 and is based in Morrisville, North ...
419 Davis Drive
Morrisville, NC 27560
Founded in 2013
Key Executives for Envisia Therapeutics Inc.
Chief Executive Officer and Director
Co-Founder, President and Chief Scientific Officer
Compensation as of Fiscal Year 2016.
Envisia Therapeutics Inc. Key Developments
Envisia Therapeutics Inc. Presents at Citi's 11th Annual Biotech Conference - Boston, Sep-08-2016 09:00 AM
Sep 1 16
Envisia Therapeutics Inc. Presents at Citi's 11th Annual Biotech Conference - Boston, Sep-08-2016 09:00 AM. Venue: The Mandarin Oriental Hotel, Boston, Massachusetts, United States. Speakers: Benjamin R. Yerxa, Co-Founder, President and Chief Scientific Officer.
Envisia Therapeutics Inc. Presents at Wedbush PacGrow Healthcare Conference 2016, Aug-17-2016 03:40 PM
Aug 9 16
Envisia Therapeutics Inc. Presents at Wedbush PacGrow Healthcare Conference 2016, Aug-17-2016 03:40 PM. Venue: Le Parker Meridien, New York, New York, United States. Speakers: Benjamin R. Yerxa, Co-Founder, President and Chief Scientific Officer.
Envisia Therapeutics Announces Positive Three-Month Interim Results of Low Dose ENV515 in Patients with Glaucoma
May 3 16
Envisia Therapeutics reported positive results from an interim three-month analysis of an ongoing 12-month safety and efficacy evaluation of the low dosage form of ENV515 XR (travoprost). ENV515, the company's product candidate, is an extended-release formulation of travoprost that could offer sustained reduction in intraocular pressure (IOP) for more than six months after a single dose. Previously, a 28-day evaluation of the low dosage form of ENV515 demonstrated a reduction in IOP comparable to topical timolol, while the high dosage form of ENV515 demonstrated results comparable to topical once-daily TRAVATAN Z® (travoprost ophthalmic solution). This second cohort of the ongoing phase 2 trial was a 12-month safety and efficacy evaluation of the low dosage form of ENV515 that was designed as an open-label trial that enrolled five glaucoma patients at sites within the U.S. The low dosage form of ENV515, administered once on Day 1, achieved the interim efficacy endpoint in this 3-month analysis, time-matched 8 AM IOP over the three-month post-dose period, with -7.1 mmHg or -27% change from IOP baseline that was comparable to topical timolol 0.5% twice daily with -7.4 mmHg or -28% change from IOP baseline, administered to the non-study eye. ENV515 was well tolerated and there were no serious adverse events, no changes in corneal endothelial cell counts evaluated by an independent reading center, and no changes in corneal thickness. The most common adverse event was early-onset transient hyperemia, or eye redness, related to the dosing procedure. ENV515 is a fully biodegradable proprietary PRINT® nanoparticle formulation of a marketed prostaglandin analog that has the potential to lower IOP for more than six months from a single dose. ENV515 has the potential to address the issue of poor patient compliance that exists present with daily eye drops and limit the progression of glaucoma that sometimes leads to vision loss. Envisia is also leveraging the company's unique platform technology to develop products for other leading ocular diseases including age-related macular degeneration (AMD), diabetic macular edema (DME), and ocular inflammation.
Similar Private Companies By Industry
Recent Private Companies Transactions
March 11, 2016